

## Conversation ID: 1270f7f67f406b52a2ee86584b452bff

Thank you. Good afternoon, and thank you all for joining us. On the call today from the Arbutus management team

We are now focused on our GalNAc conjugated subcutaneously delivered RNAi agent

and whether they have any relevance to the future development of AB-452, the class of molecules or the mechanism of action.

and it has a unique GalNAc ligands and linker, which we have specifically designed to be proprietary to us.

and work very similarly. So all I can say is that we have a number of different series that we're working on.

ways to do this and are comfortable that we have found one that is potent and durable.

We believe we have a very strong team with the skills, experience and commitment to developing a curative combination regimen for HBV patients.

We are confident the RNA destabilizing mechanism we are focused on represents a very relevant and important therapeutic target,

and that's where much of our effort is currently engaged in the immunovirology space.